Selmevit
Polycystic Ovary Syndrome
Tyumen State Medical AcademyUNKNOWNPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
61 Active assets in the Polycystic Ovary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Human Chorionic Gonadotropin Eman Basuni Ebrahim Mowad | Phase 4 | BBB |
Liraglutide Peking University Third Hospital | Phase 4 | BBB |
Semaglutide Methodist Health System | Phase 4 | BBB |
Drospirenone Ege University | Phase 4 | BBB |
Follitropin Beta Universitair Ziekenhuis Brussel | Phase 4 | BBB |
View all 49 →
Same molecule, other indications
Selmevit is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →